Extração de nemátodes de quisto de amostras de solo: método de decantação e crivagem de Cobb vs. método de Fenwick

Potato cyst nematodes are a threat to several agricultural crops around the world with some species considered quarantine pests and subjected to strict regulatory measures in many countries. Usually, cysts nematodes co-exist in the soil with other species of plant-parasitic nematodes, so, a time and cost-efficient extraction technique becomes of primary importance. The ideal extraction method should be able to obtain cysts as well as detecting the presence of other motile plant-parasitic nematodes with a potential impact on potato farming (such as Meloidogyne sp. and Pratylenchus sp.). In recent years, studies have been carried out to test the efficiency of various methods of nematode extraction but few results have been published. Therefore, to test if a method that extracts simultaneously cysts and motile nematodes can be used instead of the reference method that extracts cysts only, the efficiency of Cobb’s decanting and sieving technique was compared to Fenwick’s technique. As a result, in the 74 samples evaluated, a greater number of cysts were extracted from 24 samples using Fenwick’s method and from 11 samples employing Cobb’s decanting and sieving technique. The statistics results showed a significance level of 0,05 using Fenwick’s can allowing to conclude that this method is much more efficient than Cobb’s decanting and sieving technique, and confirming it should not be replaced by alternative methods for cysts extractioninfo:eu-repo/semantics/publishedVersio

Recreation Center Di Manado (Culture and Art Edutainment)

Kota Manado merupakan ibu kota dari provinsi Sulawesi Utara pada saat ini memiiiki visi menjadi kota pariwisata dunia dengan mengandalkan potensi sumber daya alamnya. Dengan adanya program ini maka pemerintah melakukan peningkatan pembangunan di bidang pariwisata sehingga bidang pariwisata menjadi salah satu andalan perekonomian kota Manado. Tentunya hal ini membuat pembangunan di kota Manado meningkat dengan pesat, khususnya rekreasi. Apalagi dengan budaya yang berkembang pada masyarakat Manado yaitu bersenang-senang dan suka mencari rekreasi dan hiburan. Tempat rekreasi yang ada sekarang masih kurang memfasilitasi seluruh kegiatan rekreasi, karena lokasinya yang masih terpencar-pencar. Mengingat tempat-tempat bisnis rekreasi atau recreation yang ada diprediksi akan meningkat sangat tinggi, sehingga upaya pemberadaan tempat rekreasi menjadi perhatian utama. Peluang bisnis dalam bidang recreation ini perlu diantisipasi dengan menghadirkan wadah yang khusus bergerak dalam bidang pelayanan jasa rekreasi atau recreation yang terlokalisasi dalam satu kawasan dengan fasilitas-fasilitas pelayanan dan penunjang yang cukup lengkap sehingga dapat memudahkan konsumen untuk mendapatkan yang mereka butuhkan dalam satu tempat saja.Hal ini mendasari munculnya sebuah gagasan untuk merancang suatu recreation center (pusat rekreasi) di Manado yang dapat menjadi sarana rekreasi, tempat bersenang-senang sekaligus tempat bersosialisasi bagi masyarakat Manado

Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease.

BackgroundChronic obstructive pulmonary disease (COPD) is a progressive chronic disease characterized by airflow obstruction that leads to shortness of breath and substantial negative impacts on health-related quality of life (HRQL). The course of COPD includes periodic acute exacerbations that require changes in treatment and/or hospitalizations. This study was designed to examine the responsiveness of Patient-Reported Outcomes Measurement Information System® (PROMIS®) measures to changes associated with COPD exacerbation recovery.MethodsA longitudinal analysis using mixed-effects models was conducted of people who were enrolled while stable (n = 100) and those who experienced an acute exacerbation (n = 85). PROMIS (physical function, pain interference, pain behavior, fatigue, anxiety, depression, anger, social roles, discretionary social activities, Global Health, dyspnea severity and dyspnea functional limitations) and COPD-targeted HRQL measures were completed at baseline and at 12 weeks.ResultsWe administered PROMIS measures using computer adaptive testing (CAT), followed by administration of any remaining short form (SF) items that had not yet been administered by CAT. Examination of the difference between group differences from baseline to 12 weeks in the stable and exacerbation groups revealed that the exacerbation group changed (improved) significantly more than the stable group in anxiety (p < .001 to p < .01; f2 effect size [ES] = 0.023/0.021), fatigue (p < .0001; ES = 0.036/0.047) and social roles (p < .001 to p < .05; ES = 0.035/0.024). All effect sizes were small in magnitude and smaller than hypothesized. Depression was also statistically significant (p < .05, SF only) but the ES was trivial. For all other PROMIS domains, the differences were not significant and ES were trivial.ConclusionsThis longitudinal study provides some support for the validity of the PROMIS fatigue, anxiety, and social roles domains in COPD, but further evaluation of responsiveness is warranted

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.

BACKGROUND: Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respiratory symptoms, assessed using the Evaluating Respiratory Symptoms in COPD (E-RS(™): COPD) scale (formerly EXACT-RS). METHODS: Data were pooled from the aclidinium 400 μg BID and placebo arms of two 24-week, double-blind, randomized Phase III studies evaluating aclidinium monotherapy (ATTAIN) or combination therapy (AUGMENT COPD I) in patients with moderate to severe airflow obstruction. Patients were stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) Groups A-D. Change from baseline in E-RS scores, proportion of responders (patients achieving pre-defined improvements in E-RS scores), and net benefit (patients who improved minus patients who worsened) were analyzed. RESULTS: Of 1210 patients, 1167 had data available for GOLD classification. Mean (standard deviation) age was 63.2 (8.6) years, 60.7 % were male, and mean post-bronchodilator forced expiratory volume in 1 s was 54.4 % predicted. Compared with placebo, aclidinium 400 μg BID significantly improved RS-Total (2.38 units vs 0.79 units, p < 0.001) and domain scores (all p < 0.001) at Week 24, and doubled the likelihood of being an RS-Total score responder (p < 0.05), irrespective of GOLD group. The net benefit for RS-Total (Overall: 56.9 % vs 19.4 %; A + C: 65.7 % vs 6.3 %; B + D: 56.0 % vs 20.8 %, for aclidinium 400 μg BID and placebo respectively; all p < 0.05) and domain scores (all p < 0.05) was significantly greater with aclidinium compared with placebo, in both GOLD Groups A + C and B + D. CONCLUSIONS: Aclidinium 400 μg BID significantly improved respiratory symptoms regardless of the patients' level of symptoms at baseline. Net treatment benefit was similar in patients with low or high levels of symptoms. TRIAL REGISTRATION: ATTAIN (ClinicalTrials.gov identifier: NCT01001494 ) and AUGMENT COPD I (ClinicalTrials.gov identifier: NCT01437397 )